search results for 
Logo

Fresenius group in figures

Download
€ in millions 2011 2010 2009 2008 2007
1 2008 before special items from the APP acquisition; 2009 to 2011, adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.
2 Net income attributable to Fresenius SE & Co. KGaA
3 Equity, including noncontrolling interest
4 Investments in property, plant and equipment and intangible assets, acquisitions
5 Proposal
6 2008, pro forma APP Pharmaceuticals and excluding special items from the APP acquisition
7 2009 to 2011, adjusted for the effects of the mark-to-market accounting of the MEB and the CVR
Sales and Earnings          
Sales 16,522 15,972 14,164 12,336 11,358
EBITDA 3,237 3,057 2,616 2,260 2,030
EBIT 2,563 2,418 2,054 1,7271 1,609
Net income2 7701 6601 5141 4501 410
Depreciation and amortization 674 639 562 783 421
Earnings per share in € 4.731 4.081 3.181 2.851 2.64
Cash flow and Balance sheet          
Operating cash flow 1,689 1,911 1,553 1,074 1,296
Operating cash flow in % of sales 10.2% 12.0% 11.0% 8.7% 11.4%
Total assets 26,321 23,577 20,882 20,544 15,324
Non-current assets 19,170 17,142 15,519 15,466 11,033
Equity3 10,577 8,844 7,491 6,943 6,059
Net debt 9,164 8,015 7,879 8,417 5,338
Net debt/EBITDA6 2.8 2.6 3.0 3.6 2.6
Equity ratio3 40% 38% 36% 34% 40%
Investments4 2,395 1,402 931 4,617 1,318
Profitability          
EBIT margin 15.5% 15.1% 14.5% 14.0%1 14.2%
Return on equity after taxes (ROE)6, 7 12.9% 13.3% 12.1% 10.5% 12.0%
Return on operating assets (ROOA)6 10.9% 11.6% 10.5% 9.8% 11.4%
Return on invested capital (ROIC)6 8.8% 8.9% 8.2% 7.3% 8.4%
Dividend per share in € 0.955 0.86 0.75 0.70 0.66
Employees (December 31) 149,351 137,552 130,510 122,217 114,181

€ in millions 2011 2010 2009 2008 2007
1 2008 before special items from the APP acquisition; 2009 to 2011, adjusted for the effects of the mark-to-market accounting of the MEB and the CVR. Both are non-cash items.
2 Net income attributable to Fresenius SE & Co. KGaA
3 Equity, including noncontrolling interest
4 Investments in property, plant and equipment and intangible assets, acquisitions
5 Proposal
6 2008, pro forma APP Pharmaceuticals and excluding special items from the APP acquisition
7 2009 to 2011, adjusted for the effects of the mark-to-market accounting of the MEB and the CVR
Sales and Earnings          
Sales 16,522 15,972 14,164 12,336 11,358
EBITDA 3,237 3,057 2,616 2,260 2,030
EBIT 2,563 2,418 2,054 1,7271 1,609
Net income2 7701 6601 5141 4501 410
Depreciation and amortization 674 639 562 783 421
Earnings per share in € 4.731 4.081 3.181 2.851 2.64
Cash flow and Balance sheet          
Operating cash flow 1,689 1,911 1,553 1,074 1,296
Operating cash flow in % of sales 10.2% 12.0% 11.0% 8.7% 11.4%
Total assets 26,321 23,577 20,882 20,544 15,324
Non-current assets 19,170 17,142 15,519 15,466 11,033
Equity3 10,577 8,844 7,491 6,943 6,059
Net debt 9,164 8,015 7,879 8,417 5,338
Net debt/EBITDA6 2.8 2.6 3.0 3.6 2.6
Equity ratio3 40% 38% 36% 34% 40%
Investments4 2,395 1,402 931 4,617 1,318
Profitability          
EBIT margin 15.5% 15.1% 14.5% 14.0%1 14.2%
Return on equity after taxes (ROE)6, 7 12.9% 13.3% 12.1% 10.5% 12.0%
Return on operating assets (ROOA)6 10.9% 11.6% 10.5% 9.8% 11.4%
Return on invested capital (ROIC)6 8.8% 8.9% 8.2% 7.3% 8.4%
Dividend per share in € 0.955 0.86 0.75 0.70 0.66
Employees (December 31) 149,351 137,552 130,510 122,217 114,181

Continue reading:
Summary of the fiscal year

QUICKFINDER

History

Video

My Annual report

Tools

IR-Services